

Daliresp[®] (roflumilast) – First-time generic

- On October 20, 2020, Micro Labs, Viatris, [Zydus](#), Solco, Novadoz/MSN, and [Camber launched](#) AB-rated generic versions of AstraZeneca's [Daliresp \(roflumilast\)](#) 500 mcg tablets.
 - In addition, Novadoz launched MSN's [AB-rated](#) generic version of Daliresp 250 mcg tablets.
- Daliresp is approved as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.